This multicenter cohort study pools data from more than 28 000 children with cancer who had survived 5 or more years to evaluate the optimal dose equivalence ratio for late-onset cardiomyopathy between doxorubicin and other 3 other anthracyclines (daunorubicin, epirubicin, and idarubicin) and the anthraquinone mitoxantrone.
http://bit.ly/2G1MrgO
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου